Dr Adam Ritchie
Contact information
01865 617623
Old Road Campus Research Build (ORCRB), Roosevelt Drive, Oxford OX3 7DQ
Research groups
Adam Ritchie
BSc, PhD, FHEA
Senior Vaccinologist
Douglas Group
Adam is a Senior Vaccinologist at the Jenner Institute. He is currently focused on the rabies, EBV and COVID-19 vaccine projects, alongside work on policy and regulation as part of Vax-Hub Global. Adam's interest is on translation of academic research into real world impact through the efficient development, manufacture, and clinical testing of vaccine candidates.
Adam works includes the design and delivery of early phase clinical trials, regulatory affairs, public policy, and vaccine manufacturing.
Adam is also a Lecturer in Human Science at St Catherine's College.
Recent publications
-
Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.
Ritchie AJ. et al, (2025), Vaccine, 47
-
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298
-
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671
-
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58
-
Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Dulal P. et al, (2021), Scientific reports, 11
-
Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Dulal P. et al, (2021), Scientific reports, 11
-
Making THE vaccine
Joe CCD. and Ritchie AJ., (2021), Biochemist, 43, 8 - 13
-
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
-
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
-
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288
-
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Voysey M. et al, (2021), The Lancet, 397, 99 - 111
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
-
Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation
Dulal P. et al, (2020)
-
Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components
Fedosyuk S. et al, (2019), Vaccine, 37, 6951 - 6961
-
Health and Well-being in Urban Environments
Mizdrak A. and Ritchie AJ., (2017), Building Sustainable Cities of the Future, 99 - 115
-
Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection
Ritchie AJ. et al, (2014), Retrovirology, 11
-
Normal prion protein is expressed on exosomes isolated from human plasma
Ritchie AJ. et al, (2013), British Journal of Haematology, 163, 678 - 680